Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
What adjuvant therapy would you recommend for a patient with upper tract urothelial carcinoma with neuroendocrine differentiation?
Related Questions
How would you sequence therapy for patient with metastatic RCC who was not able to tolerate TKI but now have progress on single agent IO?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
What is your treatment approach in localized RCC with VHL mutation after progression on belzutifan?
What are best practices for oncologists during the national platinum shortage?
Do you recommend pharmacological ADT for a patient with hypogonadism with unfavorable or high risk prostate cancer whose testosterone was castrate (<20) without supplementation?
How would you manage a patient with mCRPC with a good clinical and >50% reduction in PSA to Lu-PSMA but evidence of radiographic progression on PSMA PET/CT?
Would you consider adding abiraterone, in addition to ADT, for patients with less than very-high risk localized prostate cancer but high clinical-genomic metastasis risk after EBRT?
Given results of BCON trial, do you add carbogen and nicotinamide for patients receiving definitive radiotherapy for bladder cancer, particularly for non-cisplatin eligible candidates?
Will prior novel hormonal therapy affect when/how you use olaparib plus abiraterone for patients with BRCA-mutated metastatic castration resistant prostate cancer?
How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?
